Results 81 to 90 of about 3,189,219 (271)

The Impact of Chelation Therapy on Hepcidin, Ferritin, and Fertility Hormones in Female with Beta Thalassemia Major

Baghdad Journal of Biochemistry and Applied Biological Sciences
Background: Chelation therapy plays a crucial role in the management of beta-thalassemia major, a genetic disorder characterized by defective hemoglobin production, resulting in chronic anaemia and iron overload due to frequent blood transfusions ...
Heba Mohamed Hasan ALkatawe, Rayah S. Baban, Hind Shaker AL-Mamoori   +2 more
doaj   +1 more source

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study

Journal of Cardiovascular Magnetic Resonance, 2009
Background Available iron chelation regimes in thalassaemia may achieve different changes in cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four available iron chelator regimes in 232 thalassaemia major ...
Berdoussi Eleni, Zannikos Kirykos, Moraitis Panagiotis, Chouliaras Giorgos, Berdoukas Vasilios, Ladis Vassilios   +5 more
doaj   +1 more source

Persistent Zn2+ Influx‐Mediated Deacetylation of ANXA2 Regulates the “Zn2+‐Autophagic Flux” and Alleviates Intervertebral Disc Degeneration

Advanced Science, EarlyView.
Zinc transporter SLC39A14 sustains intracellular Zn2+ levels to activate SIRT3‑dependent ANXA2 deacetylation at K302. This modification weakens ANXA2‑mTOR binding and releases autophagic‑flux suppression in nucleus pulposus cells. Dysregulated Zn2+ homeostasis disrupts this axis to drive intervertebral disc degeneration.
Yuxin Jin, Yongcheng Chen, Yihao Xie, Dongyang Hu, Longhui Gong, Zhihua Chen, Linjie Chen, Minhao Gao, Qizhu Chen, Morgan Jones, Hui Wang, Xiuling You, Kenny Yat Hong Kwan, Shoutao Weng, Taidong Lyu, Xiang Chen, Yuxiao Zhu, Yusheng Wang, Bin Li, Xiangyang Wang, Xiaofeng Jia, Kailiang Zhou, Ouqiang Wu, Aimin Wu   +23 more
wiley   +1 more source

Development of a molecular-clinical predictive model for iron overload complications in beta-thalassemia major: Integrating transferrin receptor-2, ferroportin, soluble transferrin receptor, and toxic iron species (nontransferrin-bound iron)

Iraqi Journal of Hematology
BACKGROUND: Beta-thalassemia major (β-TM) is a hereditary blood disorder requiring lifelong blood transfusions, which result in iron overload and progressive organ damage.
Omar Ali Hussein, Twana Ahmed Mustafa, Sulaiman Yousif Abdulrahman Alomar   +2 more
doaj   +1 more source

Versatile Microgel Platform for Intervertebral Disc Degeneration Therapy: Targeting Pericyte‐Mediated Fibrosis and Protecting Nucleus Pulposus Cells

Advanced Science, EarlyView.
The engineered MMS@TRP microgel enables targeted, acid‐responsive delivery of a miR‐21 inhibitor to pericytes. It effectively suppresses disc fibrosis by inhibiting TGF‐β signaling while protecting nucleus pulposus cells via sustained, antioxidant tannic acid release.
Fei Ma, Zhen Zhao, Chuan Guo, Yuheng Liu, Yu Wang, Dengbo Yao, Weiqiang Lan, Dejun Zhong, Chen Fan, Yao He, Mei Zhang, Qingquan Kong, Yunfeng Lin   +12 more
wiley   +1 more source

Beliefs about chelation among thalassemia patients

Health and Quality of Life Outcomes, 2012
Background Understanding patients’ views about medication is crucial to maximize adherence. Thalassemia is a congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy.
Trachtenberg Felicia L, Mednick Lauren, Kwiatkowski Janet L, Neufeld Ellis J, Haines Dru, Pakbaz Zahra, Thompson Alexis A, Quinn Charles T, Grady Robert, Sobota Amy, Olivieri Nancy, Horne Robert, Yamashita Robert   +12 more
doaj   +1 more source

Porphyrin‐Based Porous Materials for Antibacterial Applications

Advanced Science, EarlyView.
Porphyrin‐based porous materials have excellent photophysical properties and tunable structures for high‐efficiency antibacterial therapy. This review comprehensively discusses the structural design strategies and synthetic pathways of the four main types of porphyrin‐based porous materials, summarizes their cross‐domain antimicrobial applications, and
Xiao‐Xue Liang, Xin Li, Ying Xiong, Xin Wang, Ying‐Wei Yang   +4 more
wiley   +1 more source

Refractory microcytic hypochromic anemia with type I diabetes mellitus and reversible cardiac hemochromatosis in congenital hypotransferrinemia

Pediatric Hematology Oncology Journal
Background: Hypotransferrinemia is a rare cause of anemia presenting in early childhood. The clinical scenario may mimic iron deficiency anemia at onset with no response to multiple courses of hematinics.
Shrikiran Aroor, Suneel C. Mundkur, Sandeep Kumar, Koushik Handattu, Praveen C. Samuel   +4 more
doaj   +1 more source

Iron Chelation in Thalassemia Major

, 2015
Purpose: Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity.
BORGNA, Caterina, Marsella, M.
core   +1 more source

REGIONAL SIDEROSIS: A NEW CHALLENGE FOR IRON CHELATION THERAPY [PDF]

, 2013
The traditional role of iron chelation therapy has been to reduce body iron burden via chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary routes.
Arnold eMunnich, David eDevos, Moussa B. Youdim, Arnold Munnich, Zvi Ioav Cabantchik, David Devos   +5 more
core   +1 more source